Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/08/2026 BST			5-day change	1st Jan Change
61.29 ^USD	+0.29%		+4.73%	-25.15%

07-31	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating	MT
07-15	RxSight Names Aziz Mottiwala as CEO	MT

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

a5f73690caf781752ef2959c6f468._EhsWWbflWYNQ-li6AlZkyPfcYy1pk2uxI0UsblaVbc.zHsWbQG9_1U4dogGm05r1BapPc_akhf8tOlfhugIMu_LeQt0JZbBUlshpA~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

07-31	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating	MT
04-24	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
04-23	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
03-26	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
02-25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
11-20	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/10/25	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
06/08/25	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
02/06/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
03/02/25	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
22/01/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
14/11/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
09/08/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
09/05/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
29/02/24	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
28/02/24	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
20/11/23	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
10/11/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
11/09/23	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
11/08/23	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
26/07/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
18/07/23	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT
26/06/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $44 From $40, Keeps Buy Rating	MT
16/06/23	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $42 From $40, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TARSUS PHARMACEUTICALS, INC.					+54.18%
	REGENERON PHARMACEUTICALS, INC.					+9.58%
	UCB					+28.13%
	SAMSUNG BIOLOGICS CO.,LTD.					+33.84%
	CSL LIMITED					+6.81%
	BIOGEN INC.					+12.89%
	INCYTE CORPORATION					+3.61%
	MODERNA, INC.					-10.79%
	INNOVENT BIOLOGICS, INC.					+35.82%
	BRIDGEBIO PHARMA, INC.					+29.39%
	Average					+20.35%
	Weighted average by Cap.					+16.76%